awards grant A phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents (12 to 17 years of age, inclusive) and Children (2 months to <12 years of age) with suspected or Confirmed Community-Acquired Bacterial Pneumonia.
